OpenURL Connection Search

Select item for more details and to access through your institution.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Published in:
Arthritis Research & Therapy, 2019, v. 21, n. 1, p. N.PAG, doi. 10.1186/s13075-019-1882-2
By:
- Deodhar, A.;
- Mease, P. J.;
- McInnes, I. B.;
- Baraliakos, X.;
- Reich, K.;
- Blauvelt, A.;
- Leonardi, C.;
- Porter, B.;
- Das Gupta, A.;
- Widmer, A.;
- Pricop, L.;
- Fox, T.
Publication type:
Article
Natural history of the eosinophilia-myalgia syndrome.
Published in:
1991
By:
- Culpepper, Randall C.;
- Williams, Ronald G.;
- Mease, Philip J.;
- Koepsell, Thomas D.;
- Kobayashi, John M.;
- Culpepper, R C;
- Williams, R G;
- Mease, P J;
- Koepsell, T D;
- Kobayashi, J M
Publication type:
journal article
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Published in:
2018
By:
- Walsh, J. A.;
- Gottlieb, A. B.;
- Hoepken, B.;
- Nurminen, T.;
- Mease, P. J.
Publication type:
Correction Notice
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Published in:
Clinical Rheumatology, 2018, v. 37, n. 12, p. 3285, doi. 10.1007/s10067-018-4227-7
By:
- Walsh, J. A.;
- Gottlieb, A. B.;
- Hoepken, B.;
- Nurminen, T.;
- Mease, P. J.
Publication type:
Article
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
Published in:
Arthritis Care & Research, 2017, v. 69, n. 7, p. 1030, doi. 10.1002/acr.23092
By:
- van der Heijde, D.;
- Deodhar, A.;
- Fleischmann, R.;
- Mease, P. J.;
- Rudwaleit, M.;
- Nurminen, T.;
- Davies, O.
Publication type:
Article
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
Published in:
2016
By:
- van der Heijde, D;
- Deodhar, A;
- Fleischmann, R;
- Mease, P J;
- Rudwaleit, M;
- Nurminen, T;
- Davies BPharm, O;
- Davies, O
Publication type:
journal article
Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study.
Published in:
Arthritis Care & Research, 2014, v. 66, n. 7, p. 1085, doi. 10.1002/acr.22256
By:
- Gladman, D.;
- Fleischmann, R.;
- Coteur, G.;
- Woltering, F.;
- Mease, P. J.
Publication type:
Article
Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial.
Published in:
Arthritis & Rheumatology, 2015, v. 67, n. 3, p. 668, doi. 10.1002/art.38973
By:
- Sieper, J.;
- Landewé, R.;
- Rudwaleit, M.;
- Heijde, D.;
- Dougados, M.;
- Mease, P. J.;
- Braun, J.;
- Deodhar, A.;
- Kivitz, A.;
- Walsh, J.;
- Hoepken, B.;
- Nurminen, T.;
- Maksymowych, W. P.
Publication type:
Article

Found: 8